Researcher plays down talk of anti-virus drug success
The US drug remdesivir had achieved a remarkable effect on 761 patients participating in the first day of the drug's clinical trial.
Rumor: The US drug remdesivir had achieved a remarkable effect on 761 patients participating in the first day of the drug's clinical trial.
Fact:
Remdesivir, a drug being developed by United States-based pharmaceutical company Gilead, was being tested to see whether it could be used to treat patients with pneumonia caused by the virus in Wuhan Jinyintan Hospital, in Wuhan, the outbreak epicenter, on Wednesday.
On Thursday evening rumors began spreading online saying the first day of trial had achieved a remarkable effect on 761 patients participating in the research.
But Cao Bin, vice-president of the China-Japan Friendship Hospital, dismissed this, saying research has only just started and no results have been achieved yet, according to a report by China Youth Daily.
In a statement at the end of last month, Gilead said remdesivir had not gained approval to enter the market in any country, and its safety and effectiveness had not been proven.
- Foreign delegates gain a close look at grassroots livelihood, protection of people's rights
- Primary school students tell revolutionary stories of Jinggangshan in English
- Shanxi emergency official probed after deadly mine blast
- One hundred thirty-six artifacts from Cambodia on display in Shanxi
- Hukou Waterfall roars to life after heavy upstream rainfall
- Lion King co-director heads jury at Chongqing animation festival
